⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for met mutation

Every month we try and update this database with for met mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Merestinib In Non-Small Cell Lung Cancer And Solid TumorsNCT02920996
Carcinoma, Non-...
Solid Tumor
Merestinib
18 Years - Dana-Farber Cancer Institute
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationNCT04427072
Carcinoma, Non-...
Capmatinib
Docetaxel
18 Years - Novartis
Merestinib In Non-Small Cell Lung Cancer And Solid TumorsNCT02920996
Carcinoma, Non-...
Solid Tumor
Merestinib
18 Years - Dana-Farber Cancer Institute
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationNCT04427072
Carcinoma, Non-...
Capmatinib
Docetaxel
18 Years - Novartis
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationNCT04427072
Carcinoma, Non-...
Capmatinib
Docetaxel
18 Years - Novartis
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationNCT04677595
Non-Small Cell ...
Capmatinib
18 Years - Novartis
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationNCT04677595
Non-Small Cell ...
Capmatinib
18 Years - Novartis
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsNCT04323436
Carcinoma, Non-...
Spartalizumab
Capmatinib
spartalizumab p...
18 Years - Novartis
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted TherapiesNCT05370469
Lung Cancer
EGFR Gene Mutat...
EGFR
ALK Gene Mutati...
RET Gene Mutati...
MET Gene Mutati...
KRAS Mutation-R...
BRAF
ROS1 Gene Mutat...
Sensus Smartwat...
RX Cap
Fitbit Sense
Surveys
18 Years - University of Virginia
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsNCT04323436
Carcinoma, Non-...
Spartalizumab
Capmatinib
spartalizumab p...
18 Years - Novartis
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: